41 results about "Urolithin" patented technology

Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

Disclosed is a method of preparing a urolithin, or an intermediate or analog thereof, having a dibenzo[b,d]pyran-6-one core. The method is especially advantageous for the large-scale preparation of urolithins or intermediates or analogs thereof. The method may optionally include the preparation of a urolithin, or an intermediate or analog thereof, as a pharmaceutically acceptable salt.

The invention provides compositions comprising a medium chain triglyceride and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition.

The invention provides urolithin PDE2 inhibitor compounds and a preparation method thereof, and belongs to the field of medicinal chemistry. Two types of compounds are obtained through two-step simple reaction, and 22 brand-new PDE2 inhibitor compounds are obtained in total; the method for synthesizing the compounds is simple, convenient, energy-saving and environment-friendly; in a first step, the reaction is simple, column chromatography is not needed, the purity is high, the yield is high, and the total yield is 54% or above; and in the second step, the reaction is carried out at room temperature, no by-product is generated, the purity and yield of the target product are greatly improved, the HPLC purity of the obtained compounds is high and reaches 97% or above, and the total yield is high and reaches 30.0% or above.

The invention belongs to the technical field of biological medicines, and particularly relates to an application of ellagic acid and metabolites thereof as natural inhibitors to preparation of an anti-pyroptosis medicine. The inventor finds that high glycolipid has a promotion effect on pyroptosis of pancreatic cells and liver cells, and expression levels of pyroptosis proteins GSDMD and GSDME in a pyroptosis signal path are increased, which indicates that pyroptosis plays a role in high-glucose and high-fat induced pancreatic and liver inflammatory reactions. GSDMD and GSDME mediated pyroptosis participates in diabetes pancreas and liver injury. It is found for the first time that the ellagic acid and intestinal tract metabolite uridine A thereof can inhibit GSDMD and GSDME mediated pyroptosis in an in-vivo experiment of a diabetic model mouse, and therefore, an anti-inflammatory protection effect on cells is achieved.

The invention provides application of urolithin A and derivatives thereof in tumor immunotherapy, and belongs to the technical field of biological medicine and molecular biology. According to the application, the research results show that the urolithin A and the derivatives thereof can promote the effector function of CD8 + T cells and other TCR pathway mediated activated effector T cells or artificially prepared effector T cells (including but not limited to CAR-T and TCR-T cells) so as to improve the tumor immunotherapy effect, such that the understanding of the urolithin A is effectively broadened. Regulation and control of the urolithin A on CD8 + T cell functions further reveals interaction of flora metabolites and an immune system, a theoretical basis is provided for deeply excavating more metabolites for regulating and controlling immunity, a promising immunotherapy strategy is provided for tumor patients, and therefore the urolithin A has good practical application value.

A composition comprising: a)nicotinamide riboside and b)a urolithin which is a compound of formula (I) or a salt thereof: Formula (I) wherein: A, B, C and D are each independently selected from H andOH; W, X and Y are each independently selected from H and OH; and Z is selected from H and OH. The compositions are useful as medicaments, for example for treating muscle-related pathological conditions, neurodegenerative diseases, and/or mitochondrial diseases and as dietary supplements, functional foods and beverages, and specialised nutrition or medical foods.

The application belongs to the technical field of pharmaceutical preparations and discloses application of a metabolite Urolithin A of ellagic acid in preparation of anti-enterovirus drugs, particularly drugs for preventing and treating enterovirus 71 (EV71). According to the application, through influence on titer and protein expression of the EV71 caused by UroA, it is shown that the Urolithin Acan inhibit replication of the EV71 in gene and protein levels. It is proven that the Urolithin A has an obvious anti-EV71 action and can be used for preparing anti-EV71 drugs.

The invention relates to a urolithin compound which has a structure as shown in the specification. The compound shows very strong anti-glioblastoma activity in vitro, can be matched with a medicinal carrier, and is used for preparing various medicinal dosage forms for treating anti-glioblastoma, such as capsules, granules, oral liquid or tablets.

A urolithin-containing aqueous solution containing urolithin and collagen, a dried solid composition thereof, methods for producing these, and a stabilization method for urolithin.

An object of the present invention is to provide an effective and highly safe agent for inhibiting osteoclast differentiation, and a food or drink, pharmaceutical, supplement, and cosmetic that produce an osteoclast differentiation-inhibiting effect; and the object is fulfilled by an agent for inhibiting osteoclast differentiation, comprising a urolithin.

An object of the present disclosure is, at least, to provide an enzyme that dehydroxylates hydroxyl groups at predetermined positions of urolithins having hydroxyl groups at the predetermined positions, and the object can be solved by an enzyme having the following properties (1) and (2): (1) dehydroxylating a hydroxyl group at the 4-position of urolithins; and (2) in the presence of methyl viologen (MV), being activated by one or more components selected from the group consisting of: reduced nicotinamide adenine dinucleotide (NADH); reduced nicotinamide adenine dinucleotide phosphate (NADPH); flavin adenine dinucleotide (FAD); and flavin adenine mononucleotide (FMN).